Patents Assigned to Immudyne, Inc.
-
Publication number: 20110195926Abstract: The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.Type: ApplicationFiled: August 13, 2010Publication date: August 11, 2011Applicant: ImmuDyne, Inc.Inventors: Arun K. Bahl, Sharon V. Vercellotti, John R. Vercellotti, Elias Klein
-
Publication number: 20100267661Abstract: The present invention relates to therapeutic uses of beta glucan for treating cancer, cytopenia, and symptoms associated with negative side effects of chemotherapy. As such, the current invention provides methods of using beta glucan for treating cancer, for increasing hematopoiesis, and for improving the quality of life of subjects undergoing chemotherapeutic treatment.Type: ApplicationFiled: March 17, 2010Publication date: October 21, 2010Applicant: ImmuDyne, Inc.Inventor: Alan B. Weitberg
-
Patent number: 7777027Abstract: The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.Type: GrantFiled: April 14, 2008Date of Patent: August 17, 2010Assignee: Immudyne, Inc.Inventors: Arun K. Bahl, Sharon V. Vercellotti, John R. Vercellotti, Elias Klein
-
Patent number: 7550584Abstract: The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.Type: GrantFiled: March 27, 2006Date of Patent: June 23, 2009Assignee: Immudyne, Inc.Inventors: Arun K. Bahl, Sharon V. Vercellotti, John R. Vercellotti, Elias Klein
-
Patent number: 6162787Abstract: The invention describes compositions and methods for treatment of rheumatoid arthritis and osteoarthritis. The compositions comprise insoluble, native collagen Type II in a particular form in combinations with other active agents, including glucosamine, chondroitin, ascorbate, boron and magnesium. Also described are methods for producing particulated insoluble native collagen Type II.Type: GrantFiled: April 2, 1999Date of Patent: December 19, 2000Assignee: Immudyne, Inc.Inventors: Nino Sorgente, Robert M. Nakamura
-
Patent number: 5786343Abstract: A phagocytosis-stimulating composition comprises, and preferably consists essentially of (a) a phagocytosis-stimulating substance, (b) ascorbic acid or a derivative thereof, and (c) a pharmaceutically acceptable carrier. The phagocytosis-stimulating substance suitably can be a yeast cell wall extract, such as beta-(1,3)-D-glucan. The compositions can be administered to animals to stimulate phagocytosis. The composition enhances and prolongs the stimulation of phagocytosis, by supplying ascorbic acid or an ascorbate to help replenish the ascorbate that has been depleted from the phagocytic cells such as macrophages. The composition has pharmaceutical, nutritional, and cosmetic uses, and can be used for prophylactic and therapeutic purposes.Type: GrantFiled: March 5, 1997Date of Patent: July 28, 1998Assignee: ImmuDyne, Inc.Inventor: Leonid G. Ber
-
Patent number: 4891220Abstract: Serum levels of cholesterol are improved by administration of yeast cell wall extract LCP-100 Series.TM. product LR323.TM. in combination with a cholesterol regulating agent, preferably niacin or gemfibrozil.Type: GrantFiled: July 14, 1988Date of Patent: January 2, 1990Assignee: ImmuDyne, Inc.Inventor: Byron A. Donzis
-
Patent number: D436313Type: GrantFiled: April 9, 1999Date of Patent: January 16, 2001Assignee: Immudyne, Inc.Inventors: John Joshua, Paul Schiebl